The Weekly Recap 10/17/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure new funding, announce strategic partnerships, achieve clinical milestones, and much more on the road to LSI USA ‘26 in Dana Point (March 16–20).

Adagio Medical

Announced that it entered into a securities purchase agreement worth up to $50M in proceeds, with the agreement expected to result in ~$19M in upfront proceeds. The company plans to use the funds for working capital and general corporate purposes, including the advancement of its clinical and product development activities.

Avisi Technologies

Announced that the FDA has approved an IDE submission for its VisiPlate^Ⓡ for glaucoma treatment. The SAPPHIRE trial is a prospective, multicenter, open-label clinical trial with one-year follow-up that will evaluate the safety and effectiveness of its VisiPlate aqueous shunt.

Berlin Heals

Completed enrollment in the first-in-human Phase I CMIC-III study evaluating a less invasive approach to implanting its C-MIC device. The study supports Berlin Heals’ plans to expand the new, less invasive approach to a wider population of patients and advance toward a pivotal FDA IDE trial.

CAPS Medical

Announced that its PlasmaSure™ System received Breakthrough Device Designation from the FDA for treating low- to intermediate-risk non-muscle invasive bladder cancer (NMIBC). The designation supports CAPS Medical’s mission to replace traditional TURBT, hospitalization, and general anesthesia with a simple office-based tumor ablation.

DASI Simulations

Announced a two-year co-development partnership with Cleveland Clinic to create the world’s first AI-powered “co-pilot” system for catheterization labs. Cleveland Clinic will also use DASI Simulations’ existing technology to support planning and treatment for current TAVR patients at Cleveland Clinic.

Field Medical

Announced that Circulation has published six-month outcomes from VCAS, the first-in-human trial of its FieldForce™ Ablation System, showing 82% freedom from recurrent VT/VF or ICD therapy and a 98% reduction in VT/VF burden. The results support the system’s potential to treat scar-related VT and advance Field’s FDA Breakthrough-designated program toward a pivotal trial.

Innitius

Received authorization from the Spanish Agency of Medicines and Medical Devices to initiate the pivotal international phase of its FB-CT2 study evaluating CerviSense^Ⓡ TPTL, a diagnostic tool for predicting spontaneous preterm birth. The study will enroll 357 patients across Spain and Germany to confirm device performance in real-world clinical practice.

LightHearted AI

Was awarded AI in Health feasibility funding from Innovate UK’s Biomedical Catalyst to validate the economic case for its scalable precision cardiology platform. The project supports LightHearted AI’s mission to revolutionize heart disease diagnosis through laser-based technology and advanced AI.

Nalu Medical

Announced that Boston Scientific has entered into a definitive agreement to acquire the company. Boston Scientific has been a strategic investor in Nalu Medical since 2017. Under the terms of the agreement, Boston Scientific will pay approximately $533 million in cash for the remaining equity not owned by Boston Scientific.

Neurent Medical

Announced positive two-year results from the PARAGON study evaluating the NEUROMARK^Ⓡ System for chronic rhinitis. The data, published in Ear, Nose, & Throat Journal, showed durable and clinically meaningful improvements in symptoms and quality of life across both allergic and nonallergic rhinitis subgroups.

Neuroelectrics

Announced a strategic partnership with Persyst to integrate Neuroelectrics’ wireless EEG system, Enobio^Ⓡ, with Persyst’s advanced review and analysis software. Together, the companies deliver time-synchronized EEG visualization, continuous trending, and automated spike and seizure detection.

Oxford Medical Products

Published results from a randomized, double-blind, placebo-controlled pilot trial of Sirona, its proprietary hydrogel for weight management. The study demonstrated up to 13.5% total body weight loss at 24 weeks, ~400 kcal/day average reduction in dietary intake, and strong safety and tolerability. 

Pleural Dynamics

Received a new CMS HCPCS code and NTAPC assignment for ACES™, the company’s fully implantable, automatic continuous effusion shunt system. The milestone helps expand access to the company’s FDA-cleared device, which is in its early market release phase in the U.S.

Pulse Biosciences

Announced late-breaking clinical study results from the nPulse™ Cardiac Surgical System first-in-human feasibility study for atrial fibrillation. Initial cohort study results showed 100% success in posterior box isolation in the high-dose cohort and 94% PVI success rate at three months. 

Remedy Robotics

Announced a partnership with the Australian Stroke Alliance to expand its remotely operated endovascular surgical robot to hospitals across Australia. Under the agreement, Remedy was named the Alliance’s exclusive robotics partner to expand access to rapid stroke treatment.

Smartlens

Closed a $5.2M bridge round led by Ambit Health Ventures to support FDA clearance and commercial launch of the miLens™ platform. miLens, the world’s first electronics-free contact lens capable of continuous intraocular pressure monitoring, combines microfluidic technology with AI-driven analytics to enable data-driven treatment optimization.

Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.